UCB's Keppra gets FDA approval

By Elaine Rigoli

Tampa, Fla., Aug. 2 - UCB announced that the Food and Drug Administration has approved Keppra (levetiracetam) injection 500 mg/5 mL (100 mg/mL) for use as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy.

Keppra injection is an alternative for patients when oral administration is temporarily not feasible; it must be diluted prior to use and administered as a 15-minute intravenous infusion.

In March, the European Commission approved the use of Keppra 100 mg/mL concentrate for solution for intravenous infusion for use as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adults and children four years of age and older with epilepsy.

UCB is a biopharmaceutical company with headquarters in Brussels, Belgium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.